Law360, New York (August 19, 2004, 12:00 AM ET) -- Ivax Corp.’s decision Wednesday to launch a generic version of Pfizer Inc.'s blockbuster epilepsy drug Neurontin in the midst of a drawn-out patent dispute is seen by analysts as a bold but risky move.
Ivax said Wednesday that it was carrying out only a "limited" launch to a small number of buyers, most likely pharmacy-benefit managers and managed-care organizations.
Under most state pharmacy laws, Ivax's generic tablet may not technically be substitutable for Pfizer's Neurontin in the same strengths, given that it is a tablet formulation...
Ivax Launch Of Generic Neurontin Raises Eyebrows
To view the full article, take a free trial now.
